Evaluation of a novel osteoporotic drug delivery system in vitro: Alendronate-loaded calcium phosphate cement

Orthopedics

Volumn 33, Issue 8, 2010, Pages

  Zhao, Jindong ^a   Tang, Hai ^a   Gu, Junchao ^b   Wang, Bo ^c   Bao, Li ^a   Wang, Bing Qiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF TECHNOLOGY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE CEMENT; CALCIUM PHOSPHATE;

ANIMAL CELL; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FOURIER TRANSFORMATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOPOROSIS; RAT; SCANNING ELECTRON MICROSCOPE; SUSTAINED DRUG RELEASE; X RAY DIFFRACTION;

ALENDRONATE; ANIMALS; BONE CEMENTS; BONE DENSITY CONSERVATION AGENTS; CALCIUM PHOSPHATES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; MATERIALS TESTING; MESENCHYMAL STEM CELLS; MICROSCOPY, ELECTRON, SCANNING; OSTEOPOROSIS; RATS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 77955628307     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20100625-15     Document Type: Article

References (45)

1. Li N, Ou P, Zhu H, Yang D, Zheng P. Prevalence rate of osteoporosis in the midaged and elderly in selected parts of China. Chinese Journal of Clinical Rehabilitation. Chin Med J (Engl). 2002; 115(5):773-775.
2. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Belle Mead, NJ: Exempta Medica; 1998.
3. Arkfield DG, Rubenstein E. Quest for the Holy Grail to cure arthrithis and osteoporosis: emphasis on bone drug delivery systems. Adv Drug Delivery Rev. 2005; 57(7):934-944.
4. Ginebra M.P, Traykova T, Planell JA. Calcium phosphate cements: competitive drug carriers for the musculoskeletal system? Biomaterials. 2006; 27(10):2171-2177. (Pubitemid 41782020)
5. Bohner M, Gbureck U, Barralet JE. Technological issues for the development of more efficient calcium phosphate bone cements: a critical assessment. Biomaterials. 2005; 26(33):6423-6429. (Pubitemid 41024928)
6. Apelt K, Theisis F, El-Warrak AO, et al. In vivo behavior of 3 different injectable hydraulic calcium phosphate cements. Biomaterials. 2004; 25(7-8):1439-1451.
7. Larsson S, Bauer TW. Use of injectable calcium phosphoate cement for fracture fixation: a review. Clin Orthop Relat Res. 2002; (395):23-32. (Pubitemid 34136654)
8. Ooms EM, Wolke JG, van de Heuvel MT, Jeschke B, Jansen JA. Histological evaluation of the bone response to calcium phosphate cement implanted in cortical bone. Biomaterials. 2003; 24(6):989-1000. (Pubitemid 36020388)
9. Libicher M, Hillmeier J, Liegibel U, et al. Osseous integration of calcium phosphate in osteoporotic vertebral fractures after kyphoplasty: initial results from a clinical and experimental pilot study. Osteoporosis Int. 2006; 17(8):1208-1215.
10. Nosoudi N, Moztarzadeh F, Rabiee S, et al. Using bisphosphonate as a part of calcium phosphate cement in osteoporotic patients for local loosening prevention. Bone. 2009; 44(1):68-98.
11. Fleisch H. Bisphosphonates in Bone Disease: from the Laboratory to the Patient. San Diego, CA: Academic Press; 2000.
12. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009; 360(1):53-62.
13. Huang W, Wang Y, Ren L, Du C, Shi X. A novel PHBV/hydroxyapatite microsphere releasing system loaded with alendronate. Materials Sci and Eng: C. 2009; 29(7):2221-2225.
14. Marshall JK, Thabane M, James C. Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronate. Dig Dis Sci. 2006; 51(5):864-868. (Pubitemid 44030804)
15. Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf. 2007; 30(9):755-763. (Pubitemid 47351214)
16. Poole KE, Compston JE. Osteoporosis and its management. BMJ. 2006; 333(7581):1251-1256.
17. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003; 21(22):4253-4254.
18. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002; 359(9322):2018-2026.
19. American Society for Testing and Materials. ASTM Standard C191-03: Standard Test Method for Time of Setting of Hydraulic Cement by Vicat Needle. ASTM International; 2002.
20. Jun M, Chun-rong L, Ji-fang W, et al. Physicochemical properties of calcium phosphate cement incorporated with antibiotics. Ortho J of China. 2004; 12(3, 4):230-232.
21. Kuljanin J, Jankovi I, Nedeljkovi J, Prstojevi D, Marinkovi V. Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions. J Pharm Biomed Anal. 2002; 28(6):1215-1220. (Pubitemid 34607407)
22. Wilson AP. Cytotoxicity and viability assays. In: Masters, JRW, ed. Animal Cell Culture: A Practical Approach. 3rd ed. Oxford University Press, Oxford, UK: 2000:201-210.
23. Ginebra M.P, Traykova T, Planell J.A. Calcium phosphate cements as bone drug delivery systems: A review journal of controlled release. J Control Release. 2006; 113(2):102-110.
24. Niedhart C, Maus U, Redmann E, Siebert CH. In vivo testing of a new in situ setting beta-tricalcium phosphate cement for osseous reconstruction. J Biomed Mater Res. 2001; 55(4):530-537.
25. Liu DM, Yang Q, Troczynski T, Tseng WJ. Structural evolution of sol-gel-derived hydroxyapatite. Biomaterials. 2002; 23(7):1679-1687.
26. Hofmann MP, Young AM, Gbureck U, Nazhat SN, Barralet JE. FTIR-monitoring of a fast setting brushite bone cement: effect of intermediate phases. J Mater Chem. 2006; (16):3199-3206. (Pubitemid 44182042)
27. Lo WJ, Grant DM. Hydroxyapatite thin films deposited onto uncoated and (Ti, Al, V) N-coated Ti alloys. J Biomed Mater Res. 1999; 46(3):408-417. (Pubitemid 29293765)
28. Van den Vreken NM, Pieters IY, Declercq hydroxyapatite, Cornelissen MJ, Verbeeck RM. Characterization of calcium phosphate cements modified by addition of amorphous calcium phosphate. Acta Biomater. 2010; 6(2):617-625.
29. 2- containing apatites prepared by the hydrolysis of octacalcium phosphate. Inorg Chem. 1996; (35):5791-5797.
30. Boanini E, Gazzano M, Rubini K, Bigi A. Composite nanocrystals provide new insight on alendronate interaction with hydroxyapatite structure. Adv Mater. 2007; 19(18):2499-2502. (Pubitemid 47481802)
31. Boanini E, Torricelli P, Gazzano M, Giardino R, Bigi A. Aledronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomater. 2008; 29(7):790-796. (Pubitemid 350266051)
32. Qi X, Ye J, Wang Y. Improved injectability and in vitro degradation of a calcium phosphate cement containing poly (lactide-coglycolide) microspheres. Acta Biomaterialia. 2008; 4(6):1837-1845.
33. Bohner M, Lemaitre J, Merckle HP, et al. Control of gentamicin release from a calcium phosphate admixed poly (acrylic acid). J Pharm Sci. 2000; 89(10):1262-1270.
34. Takechi M, Miyamoto Y, Ishikawa K, et al. Effects of added antibiotics on the basic properties of anti-washout-type fast-setting calcium phosphate cement. J Biomed Mater Res. 1998; 39(2):308-316. (Pubitemid 28060365)
35. Ratier A, Gibson IR, Best SM, Freche M, Lacout JL, Rodriguez F. Setting characteristics and mechanical behaviour of a calcium phosphate bone cement containing tetracycline. Biomaterials. 2001; 22(9):897-901. (Pubitemid 32201440)
36. Huang Y, Liu CS, Shao HF, Liu ZJ. Study on the applied properties of tobramycin-loaded calcium phosphate cement. Key Eng Mater. 2001; 192(1):853-860. (Pubitemid 32074058)
37. Wang X, Chen L, Xiang H, Ye J. Influence of anti-washout agents on the rheological properties and injectability of a calcium phosphate cement. 2007; 81(2):410-418.
38. Panzavolta S, Torricelli P, Bracci B, Fini M, Bigi A. Alendronate and Pamidronate calcium phosphate bone cements: Setting properties and in vitro response of osteoblast and osteoclast cells. J Inorg Biochem. 2009; 103(1):101-106.
39. Keaveny TM, Hayes WC. A 20-year perspective on the mechanical properties of trabecular bone. J Biomech Eng. 1993; 115 (4):534-542. (Pubitemid 24000878)
40. McCalden RW, McGeough JA, Court-Brown CM. Age-related changes in the compressive strength of cancellous bone. J Bone Joint Surg Am. 1997; 79(3):421-427.
41. Otsuka M, Nakahigashia Y, Matsudaa Y, Fox JL, Higuchib WI, Sugiyamac Y. A novel skeletal drug delivery system using self-setting calcium phosphate cement 7: the relationship between in vitro and in vivo drug release from indomethacin-containing cement. Journal of Control Release. 1997; 43(2,3):115-122. (Pubitemid 26390960)
42. Yun MH, Kwon K. High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetics study in humans. J Pharm Biomed Anal. 2006; 40(1):168-172. (Pubitemid 43061233)
43. Rhim SY, Park JH, Park YS, et al. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, 2-period crossover comparision in healthy Korean adult male volunteers. Clin Ther. 2009; 31(5):1037-1045.
44. Zhou S, Deng X, Li X. Investigation on a novel core-coated microspheres protein delivery system. J Control Release. 2001; 75(1-2):27-36. (Pubitemid 32635194)
45. Pignatello R, Cenni E, Micieli D, Fotia C, Salerno D, et al. A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-alendronate conjugate. Nanomedicine (Lond). 2009; 4(2):161-175.